Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
The TRIUMPH study series is evaluating the compound across several indications including obesity, type 2 diabetes, osteoarthritis, obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and MASLD
Farxiga/Forxiga (dapagliflozin) Disease area(s): Metabolic diseases Manufacturer(s): AstraZeneca 2024 Sales (USD): $7.72 billion Why it sold so well: In 2024, AstraZenecas Farxiga achieved robust sales growth, with revenues increasing by 21% year-over-year to $1.9 billion in the fourth quarter alone and by 28% compared to 2023, making it the companys top seller in 2024
"At that time, research in diabetes drugs involved significant global clinical development costs as the US FDA had laid out stringent safety regulations
Related reading on Bonza Health: References The studies cited here are available through PubMed and the publishers' websites
In adults, episodes tend to occur less frequently, but can last longer, even over a week
US$ 20.42
US$ 20.79
US$ 20.57
US$ 22.36
US$ 23.12
